EUVIMEDEUVIMED entdecken
Crossref

Risk stratification in anti‐ MDA5 + dermatomyositis‐related interstitial lung disease by using cluster analysis

Wenzhang He, Beibei Cui iD, Zhigang Chu, Xuan Huang, Jing Liu, Xue Li, Yinqiu Wang, Xueting Pang, Hui Lin, Liqing Peng iD

Journal of the European Academy of Dermatology and Venereology · 2026-03 · 40 (3) · 446-454

DOI: 10.1111/jdv.20850 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 18.07.2025. Verfasst von Wenzhang He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Dermatomyositis, Lung Diseases, Interstitial, Interferon-Induced Helicase, IFIH1, Autoantibodies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐MDA5+ dermatomyositis (DM) represents a heterogeneous group of patients as diverse individuals display different clinical characteristics, disease progression and complications development. The heterogeneity makes it difficult to classify interstitial lung disease in anti‐MDA5 antibodies positive dermatomyositis (anti‐MDA5+ DM‐ILD).

Objectives

To distinguish and characterize phenotypic subgroups for anti‐MDA5+ DM‐ILD patients.

Methods

From August 2014 to March 2022, 188 anti‐MDA5+ DM‐ILD patients were retrospectively enrolled. 21 HRCT‐derived quantitative features were reduced to four principal components through principal component analysis. The missForest algorithm was employed for missing data imputation. Clusters were determined by partitioning around medoids. The classification and regression tree (CART) algorithm was utilized to distinguish between three clusters.

Results

The Silhouette Coefficient and Dunn index indicated an optimal cluster number of 3. Patients in cluster 2 (high‐risk cluster) have the highest RP‐ILD incidence rate (84.9% vs. 18.1% vs. 17.1%, cluster 2 vs. 1 vs. 3, p < 0.001), extremely high early mortality (88.7% vs. 4.3% vs. 2.4%, cluster 2 vs. 1 vs. 3, p < 0.001) and moderate dermato‐rheumatologic pattern. Patients in cluster 1 correspond to a pure dermato‐rheumatologic pattern (dermato‐rheumatologic cluster). Cluster 3 (low‐risk cluster) was characterized by not obvious dermato‐rheumatologic and the lowest RP‐ILD incidence (17.1%) as well as the lowest early mortality (2.4%). The accuracy of the CART algorithm in differentiating clusters was 67.7% in the validation cohort with 56 patients. Principal component 1 was a key feature in the CART algorithm. Sensitivity analyses employing multiple clustering approaches confirmed the robustness of the three‐cluster solution by partitioning around medoids.

Conclusions

Clustering analysis offers valuable insights into the heterogeneity and clinical implications of anti‐MDA5+ DM‐ILD. HRCT‐derived quantitative features demonstrate significant value for early risk stratification in anti‐MDA5+ DM‐ILD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisLung Diseases, InterstitialInterferon-Induced Helicase, IFIH1AutoantibodiesHumansMaleCluster AnalysisFemaleMiddle AgedRetrospective StudiesRisk AssessmentAgedAdultAlgorithms

Stichwörter der Autor:innen

cluster analysiscomputed tomographydecision‐tree modeldermatomyositisinterstitial lung diseaserisk factor

Substanzen

Interferon-Induced Helicase, IFIH1IFIH1 protein, humanAutoantibodies

Autor:innen und Institutionen

  • Department of Radiology, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Radiology, Chongqing General Hospital, Chongqing University, Chongqing, China.
  • Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Biomedical Big Data Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  • Medical Imaging Center, West China Lecheng Hospital, Sichuan University, Qionghai, China.

ORCID-Profile: Beibei Cui, Liqing Peng

Förderung

  • Science and Technology Department of Sichuan Province
  • National Natural Science Foundation of China

Zitieren

APA

He, W., Cui, B., Chu, Z., Huang, X., Liu, J., Li, X., Wang, Y., Pang, X., Lin, H., & Peng, L. (2026). Risk stratification in anti‐ MDA5 + dermatomyositis‐related interstitial lung disease by using cluster analysis. Journal of the European Academy of Dermatology and Venereology, 40(3), 446-454. https://doi.org/10.1111/jdv.20850

Vancouver

He W, Cui B, Chu Z, Huang X, Liu J, Li X, et al. Risk stratification in anti‐ MDA5 + dermatomyositis‐related interstitial lung disease by using cluster analysis. Journal of the European Academy of Dermatology and Venereology. 2026;40(3):446-454. doi:10.1111/jdv.20850

BibTeX
@article{He2026,
  author = {He, Wenzhang and Cui, Beibei and Chu, Zhigang and Huang, Xuan and Liu, Jing and Li, Xue and Wang, Yinqiu and Pang, Xueting and Lin, Hui and Peng, Liqing},
  title = {Risk stratification in anti‐ MDA5 + dermatomyositis‐related interstitial lung disease by using cluster analysis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {3},
  pages = {446--454},
  doi = {10.1111/jdv.20850}
}
Kostenlos starten →